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Short Introduction 
 
Set-up and delivery of a clinical research project can be complicated and difficult. We 
introduce the regulatory processes involved in gaining approval for clinical research and 
discuss the obstacles that may be encountered. 
 
Main Introduction 
 
The aim of this article is to introduce key processes involved to gain approval for clinical 
research and describe some important obstacles faced by researchers. It should be noted that 
regulatory requirements depend upon both the specifications of the project and local policies. 
England and devolved administrations within the UK have different operating practices.  
 
A number of significant changes to research regulation are being implemented, as part of a 
drive to streamline and improve the set-up and delivery of clinical research studies. 
 
 
The Basics 
It is important not to underestimate the amount of preparatory work, time and support needed 
to undertake a clinical research project. Significant groundwork is needed even before a study 
is ready for research approval application. 
The basic initial requirements include a research protocol, secured funding, sponsorship (box 
1) and adequate indemnity arrangements. In addition, the specific approval requirements of 
the research project need to be established early on, as the approvals processes can be 
complicated and longwinded. Applications to most regulatory bodies are made through the 
Integrated Research Application System (IRAS), the national online research approvals and 
permissions application system 
The typical applicant requires both ethical approval and NHS site approval (‘NHS 
permission’ or ‘Research and Development (R&D) approval’) for their study. Ethical 
approval is obtained through the Research Ethics Service (RES) for all studies involving 
NHS patients or NHS property. The ethics review process is performed by research ethics 
committees (RECs). Where studies are led from England, both ethical and NHS site approval 
are arranged through a single system called ‘Health Research Authority (HRA) approval’. 
For devolved administrations, alternative applications arrangements are in place. 
 
Certain studies require Medicines and Healthcare Regulatory Agency (MHRA) approval. The 
MHRA is an agency within the Department of Health. Clinical trial authorisation (CTA) is 
issued by the MHRA for clinical trials of medicinal products (MHRA Medicines Regulation).  
Clinical investigations of non-CE marked medical devices also require MHRA review 
(MHRA Medical Devices Regulation). Other regulatory bodies issue approvals in specialised 
circumstances such as the Human Tissue Authority (HTA), Human Fertilisation and 
Embryology Authority (HFEA) and the Gene Therapy Advisory Committee (GTAC), which 
acts as the REC for gene therapy clinical research. 
 
Supporting documents are submitted with applications and include participant information 
sheets and consent forms. Guidance for preparing these forms can be found at 
www.hra.nhs.uk 
 
The project will be scrutinised by a number of bodies to ensure that the study design is 
ethically and scientifically sound, there has been adequate resource planning, the burdens and 
costs are appropriate and accurately represented and research governance standards are 
followed. The current (2005) Research Governance Framework (box 2) provides good-
practice guidance to researchers. This will be replaced in due course by a new UK-wide 
framework for health and social care research. 
 
 
 
The Health Research Authority 
 
The Health Research Authority (HRA) is an NHS body, launched in December 2011 to 
improve and streamline health research regulation whilst promoting and protecting the 
interests of patients and the public (www.hra.nhs.uk). It was set up following commitments 
made in the Government’s ‘Plan for Growth’ (2011) to tackle failings in the initiation and 
delivery of health research in the UK. This came in response to a Government -commissioned 
report by the Academy of Medical Sciences ‘A new pathway for the regulation and 
governance of health research’ (2011) which proposed, amongst other measures, creation of a 
new health research regulatory agency. 
 
The HRA oversees the Research Ethics Service (RES), which manages ethical review for 
clinical research in the UK. The functions of RES are to “protect the rights, safety, dignity 
and well-being of research participants” and “facilitate and promote ethical research that is of 
potential benefit to participants, science and society”. Since its inception the HRA has also 
taken over provision of IRAS and has combined ethics committee with R&D approvals into a 
single HRA assessment called ‘HRA Approval’. This applies to studies led from England 
only, but the HRA works closely with devolved administrations to harmonise operating 
practices within the UK. 
 
The HRA has produced a draft UK-wide Policy Framework for Health and Social Care 
Research to replace the current Research Governance Framework. At the time of writing, this 
has been through a public consultation period and is expected to come into force, after 
revisions, sometime in 2016. 
 
In line with its objectives, the HRA has close links with other bodies involved in research 
regulation and promotion such as the MHRA and National Institute for Health Research 
(NIHR).  
 
 
 
IRAS 
 
The Integrated Research Application System (IRAS) is a freely accessible online system that 
is used to prepare and submit applications for healthcare research approval. The website 
address is www.myresearchproject.org.uk. An IRAS account is simple to set up with an email 
address and chosen password. Multiple projects can be entered within a single account. 
 
Resources available to guide researchers within IRAS include an e-learning module and help 
page. Green icons attached to questions within the forms provide question-specific guidance. 
A telephone contact number and email address is also available for technical support and 
other queries. 
 
When a new project is created, it opens to a navigation page. On the left side of the page is an 
access panel for all the forms that can be captured in IRAS. For each project, information 
entered into the ‘Integrated Dataset’ of IRAS allows easy population of other forms within 
the IRAS system and avoids the need to enter duplicate information for different approvals.  
 
IRAS is designed to tailor further questions according to the responses given. Care is 
therefore needed when answering questions in the project filters. An incorrect answer can 
mean the subsequently generated questions are not appropriate for the study. 
 
Responses to the project data questions in IRAS should be carefully considered prior to 
project submission for regulatory approval. A selection of typical project data question topics 
is shown in box 3(UK Health Departments (2011), World Health Organisation 2010)). 
 
 
 
Ethical review 
 
Applications for ethical approval are submitted in IRAS and are reviewed by RECs. Each 
REC consists of lay members and people with particular expertise including healthcare 
professionals and academics.  
Most REC applications in the UK are processed through a new Central Booking Service 
(CBS), which replaces the Central Allocation System, Local Allocation System and 
Proportionate Review Allocation System*. It is still possible to apply to a specific REC of 
choice using the new service.  
The application for REC review is booked by telephone. Contact details are available on the 
HRA website www.hra.nhs.uk.  Electronic submission of all necessary documents through 
IRAS is required on the same day as booking. Before booking it is therefore important to 
have all supporting documentation ready and ensure that appropriate authorisations have been 
made.  Mandatory electronic authorisations have been introduced, meaning that all required 
signatures must be performed electronically through the IRAS system. All signatories will 
therefore need to have their own IRAS account in order to authorise. All required 
authorisations must be made before the application is submitted.  
 
It is recommended that applicants attend the REC meeting as it allows committee members to 
address queries directly with the researcher. 
 
With few exceptions, the REC must provide an opinion within 60 days of receipt of a valid 
application. Aside from a ‘favourable’ or ‘unfavourable’ opinion, a ‘favourable with 
additional conditions’ response may be issued. Alternatively the opinion can be provisional, 
pending further information or advice from a specialist referee. ‘No opinion’ may arise in a 
proportionate review case, with a recommendation for referral to a full meeting.  
 
 
*Proportionate review was introduced to speed up processing of applications that are thought to pose low risks to participants. Guidelines 
for eligibility are available on the HRA website, using the No Material Ethical Issue Tool (NMEIT). 
 
 
 
 
NHS permission 
Research taking place within an NHS organisation must be approved by the host NHS 
organisation before it starts.  Until recently, separate NHS permissions for each site were 
requested using Site-Specific Information (SSI) forms generated through IRAS. Applications 
in England are still made through IRAS but coordinated through the HRA. Separate 
coordinated system arrangements have been developed for each devolved administration in 
the UK. 
In England, each site is now asked to make a local ‘capacity and capability’ assessment. If its 
involvement in the study is then jointly agreed, arrangements are put in place to fulfil its 
requirements. The final step is confirmation that it can proceed. For non-commercial studies, 
the HRA is trialling ‘Schedule of Events’ and ‘Statement of Activities’ template documents 
for submission through IRAS, which are intended to clarify the resource requirements and 
cost implications for each site. Costs for activities are recorded in line with the Department of 
Health AcoRD guidelines (box 4). 
Prior to the introduction of the HRA Approval system it was possible for certain studies in 
England to request NHS permission through the NIHR Coordinated System for gaining NHS 
Permission (CSP). This service was provided by the NIHR Clinical Research Network 
(CRN), as part of its remit to support high quality research studies (www.crn.nihr.ac.uk). This 
role has been taken over by the HRA, but those studies adopted by the CRN continue to be 
eligible for extra practical support through NIHR (box 5). 
Obstacles to approval 
 
The UK has become a less attractive location for conducting clinical research, with evidence 
of a significant fall in the number of clinical trials undertaken. This has been largely 
attributed to difficulties in navigating processes for regulatory approvals (4). Excessively 
complex legislation, over-stringent and inconsistent interpretation of regulations and 
inadequate support of research are amongst the key obstacles identified. In response to these 
concerns, changes in regulatory mechanisms are being implemented. 
 
Obtaining NHS permission  
 
It is widely agreed that obtaining NHS permission has been one of the greatest obstacles to 
conducting a clinical trial in the UK (House of Commons Science and Technology 
Committee (2013-2014)), and widely reported as an important source of delay for multicentre 
study set-up (Al-Shahi R (2005), Mallick Andrew A et al (2009), Rees M et al (2010), 
Thompson AGH et al (2010), Snooks H et al (2012)). This is partly attributed to a 
cumbersome system of duplicate applications to every participating site, each with its own 
internal arrangements for approving research. The requirements are not always transparent 
and applications can take a significant length of time to process.  
England, Scotland, Wales and Northern Ireland have developed separate coordinated systems 
designed to improve the process of gaining NHS permission, especially across multiple sites. 
In England, the HRA has taken on the responsibility of providing a single sign-off for NHS 
centres participating in health research studies.  
The NIHR now publishes outcome data for clinical trials, which include a 70 day timeline 
from receipt of a valid research application to recruitment of the first patient.  
 
Research culture within the NHS 
 
Clinical research in the UK would benefit from a culture change; ensuring research is treated 
as a “core activity” within the NHS (Cancer Research UK (2010)).  Resistance and apathy 
towards research in the NHS can jeopardise the entire research process from project 
approvals to study completion.  Obstacles can arise in many areas including concerns about 
research costs or cost recovery and diversion of resources and staff time. Other factors 
include a lack of understanding of research processes and benefits; mistrust of research, with 
a paternalistic approach discouraging patient involvement; and simply lack of incentive to 
support research projects. Some researchers are also struggling with lack of expertise and 
inadequate training in navigating the approval process, further compounding problems 
achieving project sign-off. 
 
The Secretary of State, clinical commissioning groups and NHS England are required under 
the Health and Social Care Act 2012 (National Archives) to promote research and the use of 
research evidence. NHS England’s draft document: Research and Development Strategy 
2013-2018 “Research is everybody’s business” (NHS England (2013)), sets out aims and 
objectives to help achieve this. It isn’t entirely clear how the ambition to embed research into 
the health system will be realised and there is no quick fix. Addressing the bureaucratic 
obstacles, providing education and training, creating incentives to engage with research and 
encouraging involvement of patients and the public with research are important steps in the 
right direction.  
 
The European Clinical Trials Directive (CTD) 
 
Introduction of the Directive 2001/20/EC (European Commission (2001)) for clinical trials of 
investigational medicinal products has compromised clinical research activity in the UK by 
increasing costs and administration and extending the time required for launching new trials 
(Science and Technology Committee).This has been exacerbated by gold plating of EU 
legislation in the UK. The directive, drafted by the European Commission and enforced in the 
UK from 2004, aimed to improve regulation across the European Union and is acknowledged 
to have had favourable impact on the ethical regulation of trials in Europe. The CTD has 
since been revised in response to calls for more proportionate regulation, with largely positive 
reception. 
 
Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use 
(European Parliament (2014)) now replaces Directive 2001/20/EC. It includes the provision 
of a new EU portal and clinical trials database. The regulation will not be applied until the 
portal and database are independently assessed as being fully functional. At the time of 
writing this is predicted to be by the end of October 2018. 
 
Conclusion 
 
Healthcare research regulation and governance in the UK is overly bureaucratic, complicated 
and confusing. These difficulties are recognised and there are ongoing efforts to streamline 
approval applications and improve support so that good clinical research can continue. Some 
progress has already been made, in particular for ethics approval application, which was once 
considered a significant bureaucratic stumbling block. Measures introduced in recent years 
include the introduction of ‘multicentre’ RECs, removing the need for multiple duplicate 
applications; clear timelines for provision of a REC opinion; and introduction of IRAS. It is 
hoped that new measures such as the HRA Approval system will similarly improve the 
process of gaining NHS permission. It is clear that further work is needed. The various 
approvals processes should run in parallel and be overseen by suitably qualified and trained 
authorities who have an understanding of the regulatory/ legal/ technical aspects of the 
project. This would ensure greater consistency in approach, reduce unnecessary bureaucracy 
and help guide rather than hinder the researcher. 
 
Checks and controls must exist in research but it is important to ensure that regulatory 
scrutiny is proportionate to risk. The challenge is to ensure that the protection of the rights of 
trial participants is prioritised whilst avoiding excessive bureaucracy. However, the drive to 
improve efficiency should enhance rather than compromise ethical standards. Patients and the 
public are let down by missed opportunities to participate in good research. It is also 
unethical to squander research funding, waste research time and ultimately fail to answer 
important clinical questions because of red tape and unnecessary constraints.  
 
In addition to addressing excessive bureaucracy at national and local levels, a new culture in 
the NHS must be fostered that treats research as a core responsibility rather than simply a 
danger or a nuisance. 
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